Gilead SciencesRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Gilead Sciences (GILD) reported revenue of $7.80B in Q2 2026, with Products, Other HIV its largest revenue segment at 83%.
Gilead SciencesGilead sells HIV treatment and prevention (Biktarvy, Descovy, Yeztugo), liver-disease drugs (Livdelzi, sofosbuvir regimens), and oncology products (Trodelvy, Yescarta, Tecartus). HIV was $5.7 billion of $7.6 billion in Q2 2026 product sales.
Gilead Sciences (GILD) is a Biotechnology company. Gilead sells HIV treatment and prevention (Biktarvy, Descovy, Yeztugo), liver-disease drugs (Livdelzi, sofosbuvir regimens), and oncology products (Trodelvy, Yescarta, Tecartus). HIV was $5.7 billion of $7.6 billion in Q2 2026 product sales. It was founded in 1987, is headquartered in Foster City, California and employs about 17,000 people.
As of 2026-Q2, Gilead Sciences's revenue breaks down across Products, Other HIV (83%), Cell Therapy Products, Total Cell Therapy Product Sales (7%), Trodelvy (7%), Other Products, Total Other product sales (2%). See the revenue-by-segment chart for the full mix.
Track Gilead Sciences's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.
Sterling groups Gilead Sciences in the Healthcare sector, alongside Biogen (BIIB), Incyte (INCY) and Vertex Pharmaceuticals (VRTX).
If you are researching Gilead Sciences, also look at Biogen (BIIB), Incyte (INCY) and Vertex Pharmaceuticals (VRTX). You can compare all of them side by side or browse the full Healthcare sector on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026